PURPLE BIOTECH LTD. (PPBT)
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Purple Biotech Ltd.
Trials need funding. See this company's dilution risk and cash position.
- Phase 3Completed
Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy
Over-encapsulated 10 mg amlodipine besylate tablet, Matched placebo capsule for over-encapsulated celecoxib capsule
Hypertension
NCT02172040Enrollment152StartJun 2014Primary CompletionNov 2015CompletionNov 2015 - Phase 3Completed
Evaluation of Celecoxib Effects on Amlodipine in Subjects With Existing Hypertension Requiring Antihypertensives
OE 10 mg amlodipine besylate tablet, OE 200 mg celecoxib capsule
Hypertension
NCT02979197Enrollment105StartNov 2016Primary CompletionJul 2017CompletionJul 2017
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 3 | Completed | Over-encapsulated 10 mg amlodipine besylate tablet, Matched placebo capsule for over-encapsulated celecoxib capsule | NCT02172040 |
| Phase 3 | Completed | OE 10 mg amlodipine besylate tablet, OE 200 mg celecoxib capsule | NCT02979197 |